Lineage Relationship Between Prostate Adenocarcinoma and Small Cell Carcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Jun 1

PMID 31146720

Citations 6

Authors

Adelle D Kanan

Eva Corey

Ricardo Z N Vencio

Arjun Ishwar

Alvin Y Liu

Affiliations

Soon will be listed here.

Abstract

Background: Prostate cancer displays different morphologies which, in turn, affect patient outcome. This fact prompted questions about the lineage relationship between differentiated, more treatable prostate adenocarcinoma and poorly differentiated, less treatable non-adenocarcinoma including small cell carcinoma, and the molecular mechanism underlying prostate cancer differentiation.

Methods: Newly available non-adenocarcinoma/small cell carcinoma PDX LuCaP lines were analyzed for expression of stem cell transcription factors (scTF) LIN28A, NANOG, POU5F1, SOX2, which are responsible for reprogramming or de-differentiation. cDNA of these genes were cloned from small cell carcinoma LuCaP 145.1 into expression vectors to determine if they could function in reprogramming.

Results: Expression of scTF was detected in small cell carcinoma LuCaP 93, 145.1, 145.2, and non-adenocarcinoma LuCaP 173.1, 173.2A. Transfection of scTF from LuCaP 145.1 altered the gene expression of prostate non-small cell carcinoma cells, as well as fibroblasts. The resultant cells grew in stem-like colonies. Of note was a 10-fold lower expression of B2M in the transfected cells. Low B2M was also characteristic of LuCaP 145.1. Conversely, B2M was increased when stem cells were induced to differentiate.

Conclusions: This work suggested a pathway in the emergence of non-adenocarcinoma/small cell carcinoma from adenocarcinoma through activation of scTF genes that produced cancer de-differentiation.

Citing Articles

Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer.

Xu P, Yang J, Chen B, Ning S, Zhang X, Wang L Nat Commun. 2024; 15(1):6626.

PMID: 39103353 PMC: 11300456. DOI: 10.1038/s41467-024-50459-x.

Advances in combined neuroendocrine carcinoma of lung cancer.

Han Z, Yang F, Wang F, Zheng H, Chen X, Meng H Pathol Oncol Res. 2024; 30:1611693.

PMID: 38807858 PMC: 11130380. DOI: 10.3389/pore.2024.1611693.

Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis.

Yin J, Daryanani A, Lu F, Ku A, Bright J, Alilin A Prostate. 2024; 84(11):1033-1046.

PMID: 38708958 PMC: 11216894. DOI: 10.1002/pros.24718.

Prostate cancer research: tools, cell types, and molecular targets.

Liu A Front Oncol. 2024; 14:1321694.

PMID: 38595814 PMC: 11002103. DOI: 10.3389/fonc.2024.1321694.

The opposing action of stromal cell proenkephalin and stem cell transcription factors in prostate cancer differentiation.

Liu A BMC Cancer. 2021; 21(1):1335.

PMID: 34911496 PMC: 8675470. DOI: 10.1186/s12885-021-09090-y.

References

Olumi A, Grossfeld G, Hayward S, Carroll P, Tlsty T, Cunha G . Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59(19):5002-11. PMC: 3300837. DOI: 10.1186/bcr138. View

Burchardt T, Burchardt M, Chen M, Cao Y, de la Taille A, Shabsigh A . Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol. 1999; 162(5):1800-5. View

Freedland S, Pantuck A, Paik S, Zisman A, Graeber T, Eisenberg D . Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system. Prostate. 2003; 55(4):299-307. DOI: 10.1002/pros.10226. View

Oudes A, Roach J, Walashek L, Eichner L, True L, Vessella R . Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer. 2005; 5:86. PMC: 1187880. DOI: 10.1186/1471-2407-5-86. View

Goo Y, Goodlett D, Pascal L, Worthington K, Vessella R, True L . Stromal mesenchyme cell genes of the human prostate and bladder. BMC Urol. 2005; 5:17. PMC: 1327674. DOI: 10.1186/1471-2490-5-17. View

Oudes A, Campbell D, Sorensen C, Walashek L, True L, Liu A . Transcriptomes of human prostate cells. BMC Genomics. 2006; 7:92. PMC: 1553448. DOI: 10.1186/1471-2164-7-92. View

Yu J, Vodyanik M, Smuga-Otto K, Antosiewicz-Bourget J, Frane J, Tian S . Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858):1917-20. DOI: 10.1126/science.1151526. View

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K . Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-72. DOI: 10.1016/j.cell.2007.11.019. View

Pascal L, Deutsch E, Campbell D, Korb M, True L, Liu A . The urologic epithelial stem cell database (UESC) - a web tool for cell type-specific gene expression and immunohistochemistry images of the prostate and bladder. BMC Urol. 2007; 7:19. PMC: 2231381. DOI: 10.1186/1471-2490-7-19. View

10.

Pascal L, Vencio R, Goo Y, Page L, Shadle C, Liu A . Temporal expression profiling of the effects of secreted factors from prostate stromal cells on embryonal carcinoma stem cells. Prostate. 2009; 69(12):1353-65. DOI: 10.1002/pros.20982. View

11.

Pascal L, Vencio R, Page L, Liebeskind E, Shadle C, Troisch P . Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer. 2009; 9:452. PMC: 2809079. DOI: 10.1186/1471-2407-9-452. View

12.

Okita K, Hong H, Takahashi K, Yamanaka S . Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc. 2010; 5(3):418-28. DOI: 10.1038/nprot.2009.231. View

13.

Sun S, Sprenger C, Vessella R, Haugk K, Soriano K, Mostaghel E . Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010; 120(8):2715-30. PMC: 2912187. DOI: 10.1172/JCI41824. View

14.

Williamson S, Zhang S, Yao J, Huang J, Lopez-Beltran A, Shen S . ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol. 2011; 24(8):1120-7. PMC: 3441178. DOI: 10.1038/modpathol.2011.56. View

15.

Pascal L, Vencio R, Vessella R, Ware C, Vencio E, Denyer G . Lineage relationship of prostate cancer cell types based on gene expression. BMC Med Genomics. 2011; 4:46. PMC: 3113924. DOI: 10.1186/1755-8794-4-46. View

16.

Kumar A, White T, MacKenzie A, Clegg N, Lee C, Dumpit R . Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A. 2011; 108(41):17087-92. PMC: 3193229. DOI: 10.1073/pnas.1108745108. View

17.

Wayner E, Quek S, Ahmad R, Ho M, Loprieno M, Zhou Y . Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine. Prostate. 2011; 72(9):1023-34. DOI: 10.1002/pros.21508. View

18.

Vencio E, Nelson A, Cavanaugh C, Ware C, Milller D, Garcia J . Reprogramming of prostate cancer-associated stromal cells to embryonic stem-like. Prostate. 2012; 72(13):1453-63. DOI: 10.1002/pros.22497. View

19.

Liu A, Vencio R, Page L, Ho M, Loprieno M, True L . Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes. Cell Tissue Res. 2012; 348(3):589-600. PMC: 3367057. DOI: 10.1007/s00441-012-1383-y. View

20.

Ho M, Quek S, True L, Morrissey C, Corey E, Vessella R . Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol. 2013; 26(6):849-59. PMC: 3638070. DOI: 10.1038/modpathol.2012.238. View